← Eichor
Study identifier: NCT06948487 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy and Safety of FEXUCLUE Tab. In Patients With Acute or Chronic Gastritis

Condition: Gastritis  ·  Sponsor: Daewoong Pharmaceutical Co. LTD.

PhaseN/A
Planned participants12000
Who can joinAll sexes, 19 Years to 75 Years
Healthy volunteersNo

About this study

This study aims to evaluate the efficacy of Fexuclue tablets in improving gastrointestinal symptoms based on patient-reported outcomes (PROs), by comparing assessments before and after treatment.

This description comes directly from the study's public registry record.

Talk to the study team

So Heui Kim  ·  82-10-2994-5887  ·  2210325@daewoong.co.kr

Always discuss trial participation with your own doctor first.

Locations (1)

Masong Kim Internal Medicine ClinicSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06948487